Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 25;126(13):1645-62.
doi: 10.1161/CIRCULATIONAHA.112.105908.

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group

Valentin Fuster  1 , Deepak L Bhatt, Robert M Califf, Alan D Michelson, Marc S Sabatine, Dominick J Angiolillo, Eric R Bates, David J Cohen, Barry S Coller, Bruce Furie, Jean-Sebastien Hulot, Kenneth G Mann, Jessica L Mega, Kiran Musunuru, Christopher J O'Donnell, Matthew J Price, David J Schneider, Daniel I Simon, Jeffrey I Weitz, Marlene S Williams, W Keith Hoots, Yves D Rosenberg, Ahmed A K Hasan
Affiliations

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group

Valentin Fuster et al. Circulation. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hemostatic and thrombotic responses. Platelet and fibrin accumulation after vascular injury is intended to limit further blood loss without compounding the original injury by occluding blood flow. In this context, the optimal hemostatic response is one that is large enough to be stable, but not so large that it occludes the vascular lumen, producing downstream ischemia and further tissue damage (from Brass LF, Zhu L, Stalker TJ. Translational therapeutics at the platelet vascular interface: A CME-certified activity. Novel therapeutic targets at the platelet vascular interface. Arterioscler Thromb Vasc Biol 2008; 28:s43-s50; reprinted with permission).
Figure 2
Figure 2
The cycle of quality. Adapted from: Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood). 2007;26:62-74; reprinted with permission.
Figure 3
Figure 3
The potential role of the National Heart, Lung, and Blood Institute as a convener of therapeutic development efforts in atherothrombosis research.
See this image and copyright information in PMC

References

    1. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol. 2011;8:547–559. - PubMed
    1. Sakhuja R, Yeh RW, Bhatt DL. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol. 2010;35:123–170. - PubMed
    1. Sakhuja R, Yeh RW, Bhatt DL. Anticoagulant agents in acute coronary syndromes. Curr Probl Cardiol. 2011;36:127–168. - PubMed
    1. Kolandaivelu K, Bhatt DL. Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin. 2011;29:71–85. - PubMed
    1. Desai NR, Bhatt DL. The state of periprocedural antiplatelet therapy after recent trials. JACC Cardiovasc Interv. 2010;3:571–583. - PubMed

Publication types

MeSH terms

Substances